{
    "1689578624775573504": {
        "author_id": "194037150",
        "created_at": "2023-08-10T10:05:09.000Z",
        "edit_history_tweet_ids": [
            "1689578624775573504"
        ],
        "entities": {
            "annotations": [
                {
                    "end": 18,
                    "normalized_text": "Novo Nordisk",
                    "probability": 0.4978,
                    "start": 7,
                    "type": "Organization"
                },
                {
                    "end": 46,
                    "normalized_text": "Inversago Pharma",
                    "probability": 0.7442,
                    "start": 31,
                    "type": "Other"
                },
                {
                    "end": 112,
                    "normalized_text": "diabetes",
                    "probability": 0.6813,
                    "start": 105,
                    "type": "Other"
                }
            ],
            "hashtags": [
                {
                    "end": 6,
                    "start": 0,
                    "tag": "PRESS"
                }
            ]
        },
        "id": "1689578624775573504",
        "lang": "en",
        "public_metrics": {
            "bookmark_count": 1,
            "impression_count": 13245,
            "like_count": 94,
            "quote_count": 5,
            "reply_count": 9,
            "retweet_count": 10
        },
        "text": "#PRESS Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases"
    }
}